ADAMTS2 Antibody

What is the biological function of ADAMTS2 and why is it important to study?

ADAMTS2 plays a critical role in extracellular matrix organization through several key mechanisms. Primarily, it functions as a metalloproteinase that cleaves the propeptides of type I and II collagen prior to fibril assembly, which is essential for proper collagen formation and tissue integrity . Notably, ADAMTS2 does not act on type III collagen, demonstrating substrate specificity . Beyond collagen processing, ADAMTS2 also cleaves lysyl oxidase (LOX) at a site downstream of its propeptide cleavage site, generating a shorter LOX form with reduced collagen-binding activity .

This protein is particularly important in connective tissue development and maintenance, with highest expression observed in skin, bone, tendon, and aorta tissues, while lower expression levels are found in thymus and brain . The critical nature of ADAMTS2 is underscored by the fact that mutations in the ADAMTS2 gene cause Ehlers-Danlos syndrome type VIIC (EDS7C), a connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility, and joint hyperlaxity .

Research on ADAMTS2 contributes significantly to our understanding of collagen biosynthesis, connective tissue disorders, and extracellular matrix remodeling in both physiological and pathological contexts.

What is the molecular structure of ADAMTS2 and how does it relate to other ADAMTS family proteins?

ADAMTS2 belongs to the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) protein family, sharing several distinct protein modules with other family members while maintaining unique characteristics:

The full-length human ADAMTS2 protein has a calculated molecular weight of approximately 135 kDa, though the observed molecular weight in Western blot applications typically ranges from 110-130 kDa due to post-translational modifications . The protein is secreted and predominantly associated with the extracellular matrix , consistent with its role in collagen processing.

ADAMTS2 differs from other family members in its substrate specificity and tissue expression pattern, though it shares structural similarities with ADAMTS3, an important paralog . Understanding these structural features is crucial for developing specific antibodies and targeting strategies in research applications.

What criteria should I use when selecting an ADAMTS2 antibody for my research?

When selecting an ADAMTS2 antibody, several critical parameters must be considered to ensure experimental success:

For optimal antibody selection, review published literature utilizing ADAMTS2 antibodies in applications similar to your planned experiments. Additionally, examine validation data provided by manufacturers, including Western blot images showing the expected molecular weight (110-130 kDa for ADAMTS2) and specificity controls .

Importantly, consider whether the antibody has been validated in the specific tissue or cell type you intend to study, as ADAMTS2 expression varies significantly across tissues, with highest levels in skin, bone, tendon, and aorta .

How can I rigorously validate an ADAMTS2 antibody for specificity before using it in my experiments?

Rigorous validation of ADAMTS2 antibodies requires a multi-faceted approach:

• Positive and negative control samples:

  • Positive controls: Use cell lines with confirmed ADAMTS2 expression such as A431, A375, PC-3, THP-1, COLO 205, or HT-1080 cells

  • Negative controls: Use ADAMTS2 knockout cells, siRNA knockdown samples, or tissues known to express minimal ADAMTS2 (with caution as even low-expressing tissues may have some signal)

• Western blot validation:

  • Verify the observed molecular weight matches the expected 110-130 kDa range for ADAMTS2

  • Test antibody performance across dilution ranges (e.g., 1:5000-1:50000)

  • Include loading controls and molecular weight markers

  • Consider tissue-specific post-translational modifications that may affect migration pattern

• Immunohistochemistry validation:

  • Compare staining patterns with known ADAMTS2 expression patterns

  • Use multiple antibodies targeting different epitopes to confirm localization

  • Include appropriate controls for background staining (secondary antibody only, isotype controls)

  • Test multiple antigen retrieval methods (e.g., TE buffer pH 9.0 or citrate buffer pH 6.0)

• Cross-reactivity assessment:

  • Test potential cross-reactivity with other ADAMTS family members, particularly close paralogs like ADAMTS3

  • Use immunoprecipitation followed by mass spectrometry to confirm antibody specificity

• Genetic validation approaches:

  • Compare antibody staining in wild-type versus ADAMTS2 knockout or knockdown models

  • Perform rescue experiments with ADAMTS2 overexpression in knockout systems to confirm specificity

For comprehensive validation, document all validation steps methodically and consider pre-absorption tests with the immunizing peptide when available to confirm specificity.

What are the optimal conditions for using ADAMTS2 antibodies in Western blot applications?

Optimizing Western blot conditions for ADAMTS2 detection requires careful consideration of multiple variables:

Key considerations for successful ADAMTS2 Western blots:

• Sample preparation: ADAMTS2 is sensitive to proteolytic degradation, so use fresh samples with protease inhibitors. For secreted ADAMTS2, analyze both cell lysates and concentrated conditioned media.

• Expected molecular weight: ADAMTS2 typically appears between 110-130 kDa , but may show additional bands due to proteolytic processing or post-translational modifications.

• Positive controls: Include lysates from cells known to express ADAMTS2, such as A431, COLO 205, PC-3, or HT-1080 cells .

• Troubleshooting: If signal is weak, try increasing protein loading, longer exposure times, or more sensitive detection reagents. For high background, optimize blocking conditions and increase washing stringency.

How should I approach ADAMTS2 immunostaining in tissue sections for optimal results?

Successful immunohistochemical detection of ADAMTS2 in tissue sections requires careful optimization of multiple parameters:

Tissue-specific considerations for ADAMTS2 immunostaining:

• Target tissues: ADAMTS2 is highly expressed in skin, bone, tendon, and aorta, making these optimal tissues for positive controls . Expression is lower in thymus and brain.

• Expected localization: ADAMTS2 is primarily extracellular and associated with the extracellular matrix . Confirm that staining patterns show appropriate extracellular distribution.

• Validation controls:

  • Positive tissue controls (e.g., skin, aorta)

  • Negative controls (omitting primary antibody)

  • Competing peptide controls (when available)

  • Comparison with mRNA expression data from public databases

• Specialized tissues: For mineralized tissues like bone, decalcification may be necessary but can affect epitope availability. Consider alternatives like plastic embedding with methylmethacrylate for undecalcified sections when studying ADAMTS2 in bone contexts.

What are common challenges in detecting ADAMTS2 and how can I overcome them?

Researchers frequently encounter several challenges when working with ADAMTS2 antibodies, which can be addressed through strategic approaches:

When interpreting ADAMTS2 detection data, consider these biological factors:

• Processing forms: ADAMTS2 undergoes proteolytic processing, so multiple bands may represent biologically relevant forms rather than non-specific binding.

• Tissue-specific expression: Expression levels vary dramatically between tissues, with highest levels in skin, bone, tendon and aorta, and lower levels in thymus and brain .

• Cellular localization: ADAMTS2 is secreted and associates with the extracellular matrix , so cellular fractionation may affect detection efficiency.

• Physiological regulation: TGF-β1 regulates ADAMTS2 , so cellular treatment conditions may alter expression levels.

How can I differentiate between ADAMTS2 and other closely related ADAMTS family members in my experimental system?

Distinguishing ADAMTS2 from related family members requires careful experimental design and validation:

• Antibody specificity validation:

  • Compare sequence homology between ADAMTS2 and related proteins, particularly ADAMTS3 (a close paralog)

  • Test antibodies against recombinant ADAMTS proteins to determine cross-reactivity

  • Validate with genetic approaches (siRNA, CRISPR) targeting specific family members

  • When possible, use antibodies raised against unique regions with low homology to other ADAMTS proteins

• Molecular approaches for verification:

  • Use RT-qPCR with gene-specific primers to correlate protein detection with mRNA expression

  • Employ immunoprecipitation followed by mass spectrometry for definitive identification

  • Consider proximity ligation assays with antibodies targeting different epitopes for confirmation

• Functional discrimination:

  • ADAMTS2 specifically cleaves type I and II collagen propeptides but not type III collagen

  • Design functional assays based on this substrate specificity

  • Assess enzyme activity using specific fluorogenic or chromogenic substrates

• Expression pattern analysis:

  • Compare detection results with known tissue distribution patterns (ADAMTS2 highest in skin, bone, tendon, aorta)

  • Cellular localization (secreted and ECM-associated) can help distinguish from family members with different localizations

• Control experiments:

  • Include parallel experiments with tissues from ADAMTS2 knockout models

  • Use tissues or cells with known differential expression of ADAMTS family members

  • Consider rescue experiments with specific ADAMTS protein expression

For comprehensive analysis, combine multiple approaches to build a strong case for specific ADAMTS2 detection rather than relying solely on antibody-based methods.

How can I effectively use ADAMTS2 antibodies in complex experimental systems like co-immunoprecipitation or ChIP studies?

Employing ADAMTS2 antibodies in advanced applications requires specialized protocols and considerations:

Co-immunoprecipitation (Co-IP) with ADAMTS2:

• Antibody selection:

  • Use antibodies validated for immunoprecipitation such as the ADAMTS-2 Antibody (F-4) AC (sc-393562 AC)

  • Consider antibodies targeting different epitopes to avoid interference with protein interactions

  • Test multiple antibodies as epitope accessibility may differ in native protein complexes

• Experimental optimization:

  • For secreted ADAMTS2, concentrate conditioned media before immunoprecipitation

  • Use mild lysis conditions to preserve protein-protein interactions

  • Include appropriate controls (IgG control, input sample, knockout/knockdown controls)

  • Consider crosslinking approaches for transient or weak interactions

• Analysis of interacting partners:

  • Examine known ADAMTS2 interactions with collagen precursors and other extracellular matrix components

  • Use mass spectrometry for unbiased identification of interaction partners

  • Confirm interactions with reciprocal Co-IP when possible

  • Validate biological relevance with functional assays

Chromatin Immunoprecipitation (ChIP) considerations:

• Use ChIP to investigate transcription factors binding to the ADAMTS2 promoter

• Consider ChIP-seq approaches to identify genome-wide binding sites for transcription factors regulating ADAMTS2

• Correlate ChIP data with ADAMTS2 expression levels under different conditions

Proximity Ligation Assays (PLA):

• Combine ADAMTS2 antibodies with antibodies against suspected interaction partners

• Optimize fixation and permeabilization to preserve extracellular interactions

• Validate specificity with appropriate controls (single antibody, competing peptides)

What strategies exist for studying ADAMTS2 in the context of extracellular matrix remodeling and disease models?

Advanced research on ADAMTS2 in extracellular matrix remodeling and disease contexts requires sophisticated experimental approaches:

Advanced techniques for functional ADAMTS2 analysis:

• Activity-based probes:

  • Develop fluorescent or biotinylated substrates based on collagen propeptide sequences

  • Monitor ADAMTS2 enzymatic activity in real-time in living systems

  • Correlate protein levels (detected by antibodies) with functional activity

• Genetic manipulation approaches:

  • CRISPR/Cas9 modification of ADAMTS2 in relevant cell types

  • Conditional knockout models to study tissue-specific functions

  • Knock-in reporter systems to monitor expression dynamics

• Live imaging strategies:

  • Antibody-based detection of secreted ADAMTS2 in living tissues

  • Correlative light and electron microscopy to link ADAMTS2 localization with ultrastructural features

  • Intravital microscopy to study ADAMTS2 in tissue remodeling in vivo

• Therapeutic targeting validation:

  • Use antibodies to validate targeting approaches in disease models

  • Develop blocking antibodies that inhibit ADAMTS2 activity

  • Employ antibodies to monitor response to experimental therapeutics

For disease-specific applications, carefully characterize baseline ADAMTS2 expression and function in your model system before experimental intervention, using antibodies validated for your specific application and species .

How might novel antibody-based technologies enhance ADAMTS2 research in the coming years?

Emerging antibody technologies offer promising avenues for advancing ADAMTS2 research:

• Single-domain antibodies and nanobodies:

  • Smaller size allows better tissue penetration for in vivo imaging

  • Enhanced access to cryptic epitopes within the complex ADAMTS2 structure

  • Potential for intrabody applications to track ADAMTS2 in living cells

• Bi-specific and multi-specific antibodies:

  • Simultaneous targeting of ADAMTS2 and its substrates or interaction partners

  • Creation of molecular bridges to study protein complexes in situ

  • Enhanced specificity through recognition of multiple epitopes

• Antibody-enzyme fusion proteins:

  • Direct conjugation of reporters to enable real-time monitoring of ADAMTS2 dynamics

  • Development of proximity-dependent labeling systems to identify transient interaction partners

  • CRISPR-antibody fusions for targeted genomic modification at ADAMTS2 expression sites

• Activatable antibody systems:

  • Antibodies that change conformation or activity upon binding to ADAMTS2

  • Environment-responsive antibodies that detect ADAMTS2 only under specific conditions

  • Photoswitchable antibodies for spatiotemporal control of ADAMTS2 detection

• Intracellular antibody delivery systems:

  • Nanoparticle-based delivery of ADAMTS2 antibodies to track intracellular processing

  • Cell-penetrating peptide conjugates for monitoring ADAMTS2 trafficking

  • mRNA delivery systems for in situ antibody production

These emerging technologies will enable researchers to address currently challenging questions about ADAMTS2 biology, including its temporal dynamics during matrix remodeling, the stoichiometry of its interactions with substrates, and its precise localization within tissue microenvironments.

What are the challenges and opportunities in translating ADAMTS2 research findings to clinical applications?

Translational research involving ADAMTS2 presents specific challenges and opportunities:

Methodological considerations for translational applications:

• Assay standardization:

  • Develop quantitative standards for ADAMTS2 detection

  • Create reference materials for calibration across laboratories

  • Establish protocols that minimize pre-analytical variables

• Biospecimen considerations:

  • Test antibody performance in clinically relevant sample types (FFPE tissues, serum, biofluids)

  • Evaluate stability of ADAMTS2 epitopes during clinical sample processing

  • Develop extraction protocols optimized for different biospecimen types

• Validation requirements:

  • Expand validation beyond research applications to clinical standards

  • Assess antibody performance across diverse patient populations

  • Consider regulatory requirements for diagnostic applications

• Integration with other biomarkers:

  • Develop multiplex assays combining ADAMTS2 with related markers

  • Correlate ADAMTS2 detection with standard clinical parameters

  • Create algorithms incorporating multiple markers for improved sensitivity/specificity

The transition from research to clinical applications requires collaborative efforts between antibody developers, basic researchers, and clinical scientists to ensure that ADAMTS2 detection methods are robust, reproducible, and clinically meaningful.